Hegde et al. reported the efficacy of combining a HER2 scFv and an IL-13Rα2-binding IL-13 mutant and using CD28 as the costimulatory factor against GBM cells and xenograft GBM [53]. Here, IL13RA2 is linked to glioblastoma.